Rockefeller Capital Management
MLYS icon

Rockefeller Capital Management’s Mineralys Therapeutics MLYS Stock Holding History

Rockefeller Capital Management’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15K Buy
555
+421
+314% +$12.3K ﹤0.01% 3830
2025
Q4 		$4.86K Buy
134
+103
+332% +$4.13K ﹤0.01% 4079
2025
Q3 		$1.18K Buy
+31
New +$671 ﹤0.01% 4167

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Rockefeller Capital Management's MLYS Position: Q1 2026 in Review

Rockefeller Capital Management increased its Mineralys Therapeutics (MLYS) stake by 314% in Q1 2026, buying an estimated $12.3K and bringing the position to 555 shares worth $15K. The position accounts for ﹤0.01% of the portfolio, ranked #3830.

Rockefeller Capital Management first reported a position in MLYS in Q3 2025 and has held it in 3 quarters since. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • Rockefeller Capital Management held 555 shares of Mineralys Therapeutics worth $15K as of Q1 2026.
  • Rockefeller Capital Management bought 421 Mineralys Therapeutics shares in Q1 2026, an estimated $12.3K.
  • Mineralys Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #3830 holding.
  • Rockefeller Capital Management first reported a position in Mineralys Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.